INSM Insmed Inc

/C O R R E C T I O N -- Insmed Inc./ In the news release "Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)" issued May 5 over PRNewswire, we are advised by a representative of the company that the domestic dial-in number in the second paragraph, first sentence, should be "877-407-8035" rather than "877-407-2035" as originally issued inadvertently. Complete, corrected release follows: RICHMOND, Va., May 5 /PRNewswire-FirstCall/ -- Insmed Incorporated (NASDAQ:INSM), a developer of pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs, will host a conference call Thursday May 12, 2005 at 8:30 a.m. (ET). Geoffrey Allan, CEO, and Kevin Tully, CFO, will announce the first quarter financial results and provide a corporate update. To participate in the call, dial 877-407-8035 (domestic) or 201-689-8035 (international). The call will be webcast live through Insmed's corporate website, http://www.insmed.com/, and will be archived until November 12, 2005. About Insmed Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit http://www.insmed.com/ . Statements included within this press release that are not historical in nature may constitute forward-looking statements for purposes of the safe harbour provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding clinical trials and goals, our regulatory and business strategies and growth opportunities for existing or proposed products. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the company may lack financial resources to complete development of product candidates, the FDA may interpret the results of our studies differently than we have, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release. DATASOURCE: Insmed Incorporated CONTACT: Baxter Phillips, III, Investor Relations of Insmed Incorporated, +1-804-565-3041, or fax, +1-804-565-3510, or Web site: http://www.insmed.com/

Copyright